%0 Journal Article %T FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab Failure for COlorectal Cancer (BEFLICO): An AGEO Multicenter Study %+ Laboratoire de Recherche en Sciences Végétales (LRSV) %+ Institut Bergonié [Bordeaux] %+ Institut Curie [Paris] %+ Ethologie animale et humaine (EthoS) %+ Institut Mondor de Recherche Biomédicale (IMRB) %+ Centre hospitalier universitaire de Poitiers (CHU Poitiers) %+ CHU Pitié-Salpêtrière [AP-HP] %+ Groupe hospitalier de La Rochelle %+ Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon) %+ Centre Hospitalier Universitaire [Grenoble] (CHU) %+ Université Grenoble Alpes (UGA) %+ CHU Limoges %+ Hopital de Bohars - CHRU Brest (CHU - BREST ) %+ Centre Hospitalier Universitaire d'Angers (CHU Angers) %+ Centre Hospitalier Universitaire de Toulouse (CHU Toulouse) %+ Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL) %+ Commissariat à l'énergie atomique et aux énergies alternatives - Laboratoire d'Electronique et de Technologie de l'Information (CEA-LETI) %+ Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO) %+ Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille) %+ Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 (CANTHER) %+ Sorbonne Université - Faculté de Médecine (SU FM) %+ Université de Reims Champagne-Ardenne (URCA) %+ Centre Hospitalier Universitaire de Reims (CHU Reims) %+ AP-HP - Hôpital Bichat - Claude Bernard [Paris] %+ Nutrition, croissance et cancer (U 1069) (N2C) %+ Groupe innovation et ciblage cellulaire (GICC), EA 7501 [2018-...] (GICC EA 7501) %+ Centre Hospitalier Régional Universitaire de Tours (CHRU Tours) %+ Communications Cellulaires et Différenciation (CCD) %+ Centre Hospitalier de Meaux %+ Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX) %+ Hôpital Louis Domergue [CHU de la Martinique] %+ Clinique de l'Estrée %+ Hôpital Européen Georges Pompidou [APHP] (HEGP) %+ Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL) %+ Hôpital Paul Brousse %+ Polyclinique Bordeaux Nord Aquitaine (PBNA) %+ Bordeaux population health (BPH) %+ CHU Saint-Antoine [AP-HP] %+ Institut Jean Godinot [Reims] %+ Centre Hospitalier Boulogne-sur-mer %+ Cancer Research and Personalized Medicine - CARPEM [Paris] %+ Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)) %A Torregrosa, Cécile %A Pernot, Simon %A Vaflard, Pauline %A Perret, Audrey %A Tournigand, Christophe %A Randrian, Violaine %A Doat, Solene %A Neuzillet, Cindy %A Moulin, Valérie %A Stouvenot, Morgane %A Roth, Gael %A Darbas, Tiffany %A Auberger, Benjamin %A Godet, Tiphaine %A Jaffrelot, Marion %A Lambert, Aurélien %A Dubreuil, Olivier %A Gluszak, Cassandre %A Bernard-Tessier, Alice %A Turpin, Anthony %A Palmieri, Lola-Jade %A Bouche, Olivier %A Goujon, Gael %A Lecomte, Thierry %A Sefrioui, David %A Locher, Christophe %A Grados, Lucien %A Gignoux, Pauline %A Trager, Stéphanie %A Nassif, Elise %A Saint, Angélique %A Hammel, Pascal %A Lecaille, Cédric %A Bureau, Mathilde %A Perrier, Marine %A Botsen, Damien %A Bourgeois, Vincent %A Taieb, Julien %A Auclin, Edouard %< avec comité de lecture %@ 0020-7136 %J International Journal of Cancer %I Wiley %8 2022 %D 2022 %R 10.1002/ijc.34166 %Z Life Sciences [q-bio]/Human health and pathologyJournal articles %X After failure of first line FOLFOX-bevacizumab for metastatic colorectal cancer (mCRC), adding either bevacizumab or aflibercept to second-line FOLFIRI increases survival compared to FOLFIRI alone. In this French retrospective multicentre cohort, we included patients with a mCRC treated with either FOLFIRI-aflibercept or FOLFIRI-bevacizumab. The primary endpoint was overall survival (OS), and secondary endpoints were progression-free survival (PFS), disease control rate (DCR: CR\,+\,PR\,+\,SD) and safety. We included 681 patients from 36 centers, 326 and 355 in the aflibercept and bevacizumab groups, respectively. Median age was 64.2\,years and 45.2% of patients were men. Most patients had RAS-mutated tumors (80.8%) and synchronous metastases (85.7%). After a median follow up of 31.2~months, median OS was 13.0~months (95% CI: 11.3-14.7) and 10.4~months (95% CI: 8.8-11.4) in the bevacizumab and aflibercept groups, respectively (P\,<\,.0001). Median PFS was 6.0~months (95% CI: 5.4-6.5) and 5.1~months (95% CI: 4.3-5.6) (P\,<\,.0001). After adjustment on age, PS, PFS of first line, primary tumor resection, metastasis location and RAS/BRAF status, bevacizumab was still associated with better OS (HR: 0.71, 95% CI: 0.59-0.86, P~=~.0003). FOLFIRI-bevacizumab combination was associated with longer OS and PFS, and a better tolerability, as compared to FOLFIRI-aflibercept after progression on FOLFOX-bevacizumab. %G English %L hal-03735625 %U https://u-picardie.hal.science/hal-03735625 %~ INERIS %~ CEA %~ RIIP %~ EPHE %~ UNIV-TLSE3 %~ UNIV-RENNES1 %~ UGA %~ UNIV-TOURS %~ CNRS %~ UNIV-PICARDIE %~ UNIV-LYON1 %~ URCA %~ INRA %~ APHP %~ FNCLCC %~ BERGONIE %~ CURIE %~ VAUTRIN %~ LACASSAGNE %~ GODINOT %~ ICO %~ IMRB %~ ETHOS %~ UPEC %~ UNAM %~ CORDELIERS %~ COMUE-NORMANDIE %~ DRT %~ UR1-UFR-SVE %~ UR1-HAL %~ PSL %~ UR1-SDV %~ AGREENIUM %~ UNIV-COTEDAZUR %~ LETI %~ TEST-UR-CSS %~ UNIV-RENNES %~ UNIV-LILLE %~ UNICAEN %~ CHU-UNIV-PARIS5 %~ SORBONNE-UNIVERSITE %~ SORBONNE-UNIV %~ CEA-GRE %~ SU-MEDECINE %~ SU-SCIENCES %~ TEST-DEV %~ SU-MED %~ UDL %~ UNIV-LYON %~ INRAE %~ UNIV-PARIS %~ UNIVERSITE-PARIS %~ UP-SANTE %~ EPHE-PSL %~ INSTITUT-CURIE-PSL %~ CANTHER %~ UGA-EPE %~ UR1-BIO-SA %~ U1219 %~ U-PICARDIE %~ PERITOX %~ LRSV %~ ALLIANCE-SU %~ UNIV-UT3 %~ UT3-INP %~ UT3-TOULOUSEINP %~ N2C